Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein kinase C modulation.

H H Grunicke1, F Uberall

  • 1Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Austria.

Seminars in Cancer Biology
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota.

The Biochemical journal·2001
Same author

Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras.

The Journal of biological chemistry·2001
Same author

Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells.

The Journal of biological chemistry·2001
Same author

Elements of signal transduction in drug discovery with special reference to inhibitors of protein kinase C.

Ernst Schering Research Foundation workshop·2001
Same author

Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling.

The Journal of biological chemistry·2001
Same author

T cell expressed PKCtheta demonstrates cell-type selective function.

European journal of immunology·2001

Protein kinase C (PKC) modulators are promising anti-tumor agents that enhance chemotherapy effectiveness. They overcome drug resistance by inhibiting efflux pumps and interfering with cellular repair mechanisms.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Protein kinase C (PKC) modulators are recognized for their potential as anti-tumor agents.
  • Drug resistance, particularly multidrug resistance (mdr)-mediated drug efflux, remains a significant challenge in cancer therapy.
  • Ras-induced resistance to platinum-based chemotherapeutics limits treatment efficacy.

Purpose of the Study:

  • To evaluate the role of PKC modulators in overcoming cancer drug resistance.
  • To investigate the mechanisms by which PKC modulators enhance the efficacy of DNA-damaging agents like platinum complexes.
  • To explore the potential of PKC modulators in counteracting ras-induced chemoresistance.

Main Methods:

  • The study likely involved in vitro assays to assess antiproliferative effects.

Related Experiment Videos

  • Mechanisms of drug efflux inhibition and interference with DNA repair pathways were investigated.
  • Experiments were designed to analyze the antagonism of p21ras functions in the context of platinum resistance.

    • Main Results:

    • PKC modulators demonstrated antiproliferative activity against tumor cells.
    • These agents were found to inhibit mdr-mediated drug efflux, a key mechanism of drug resistance.
    • PKC modulators enhanced the cytotoxicity of platinum complexes, suggesting interference with detoxification and repair processes.
    • Evidence suggests PKC modulators can overcome ras-induced cis-platinum resistance by antagonizing p21ras.

    Conclusions:

    • PKC modulators are valuable anti-tumor agents with the potential to overcome multidrug resistance.
    • Their ability to inhibit drug efflux and interfere with cellular repair mechanisms enhances chemotherapy efficacy.
    • PKC modulators show promise in overcoming specific resistance pathways, such as those mediated by ras.
    • Further research into PKC modulators could lead to novel therapeutic strategies for resistant cancers.